Education
About Us
Working with TipRanks
Follow Us
IDEV - ETF AI Analysis
Top Page
iShares Core MSCI International Developed Markets ETF (IDEV)
Rating:66Neutral
Price Target:
$85.00
Positive Factors
Strong Top Holdings
Several of the ETF's largest positions, such as ASML Holding NV and Nestlé SA, have delivered strong year-to-date performance, supporting overall returns.
Low Expense Ratio
The ETF has an exceptionally low expense ratio of 0.04%, making it a cost-effective choice for investors.
Broad Geographic Diversification
The fund is diversified across multiple developed markets, including Japan, the UK, and Germany, reducing reliance on any single country.
Negative Factors
Underperforming Holdings
Some top holdings, such as SAP SE, have lagged in year-to-date performance, potentially dragging on overall returns.
Sector Concentration in Financials
The ETF has significant exposure to the financial sector, which may increase vulnerability to sector-specific risks.
Limited U.S. Exposure
With only 11.38% allocated to U.S. companies, the ETF may underperform during periods of strong U.S. market growth.
IDEV vs. SPDR S&P 500 ETF (SPY)
AUM22.57B
RegionDeveloped Markets
Expense Ratio0.04%
Beta0.72
IssueriShares
Inception DateMar 21, 2017
Dividend Yield2.87%
Asset ClassEquity
Index TrackedMSCI World ex USA IMI
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume1,439,545
30 Day Avg. Volume1,393,758
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
89.60Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering2248
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
IDEV Summary
The iShares Core MSCI International Developed Markets ETF (IDEV) is a fund that lets you invest in a wide range of companies from developed countries outside the U.S. and Canada. It includes businesses from places like Japan, the UK, and Germany, and covers industries such as finance, technology, and healthcare. Some well-known companies in the fund are Nestlé and AstraZeneca. IDEV is a great option for investors looking to diversify their portfolio globally and tap into international growth opportunities. However, since it tracks the performance of global markets, its value can rise or fall depending on how those markets perform.
How much will it cost me?The iShares Core MSCI International Developed Markets ETF (IDEV) has an expense ratio of 0.04%, meaning you’ll pay $0.40 per year for every $1,000 invested. This is lower than average because it’s a passively managed fund that tracks an index, which typically costs less to operate compared to actively managed funds.
What would affect this ETF?Positive drivers for IDEV could include economic growth in developed markets outside the U.S., particularly in sectors like financials, technology, and healthcare, which are heavily represented in the ETF. However, negative factors such as rising interest rates or geopolitical tensions in Europe and Asia could impact the performance of key holdings like ASML, Nestlé, and HSBC, as well as broader sector trends like energy and industrials. Regulatory changes or currency fluctuations in these regions may also affect returns.
IDEV Top 10 Holdings
The IDEV ETF showcases a diverse lineup of international heavyweights, with a notable tilt toward financials and industrials. Roche Holding and AstraZeneca are rising stars, buoyed by strong pipelines and strategic progress in healthcare, while HSBC adds momentum with steady growth and favorable dividends. On the flip side, SAP and Siemens are lagging, weighed down by bearish technical trends and mixed sentiment in the industrial sector. With its broad exposure to developed markets outside the U.S., the fund offers a balanced approach, though its reliance on financials and healthcare could make it sensitive to sector-specific shifts.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| ASML Holding NV | 1.58% | $361.51M | €318.58B | 30.04% | 76 Outperform | |
| AstraZeneca | 1.07% | $245.11M | £214.25B | 31.94% | 76 Outperform | |
| Roche Holding AG | 1.06% | $241.61M | CHF252.45B | 36.57% | 73 Outperform | |
| Nestlé SA | 0.99% | $227.00M | CHF204.13B | 16.22% | 71 Outperform | |
| SAP SE | 0.97% | $220.53M | €239.26B | -9.26% | 66 Neutral | |
| Novartis AG | 0.94% | $215.60M | CHF195.80B | 9.82% | 80 Outperform | |
| HSBC Holdings | 0.94% | $213.89M | £178.86B | 43.76% | 79 Outperform | |
| Shell (UK) | 0.84% | $192.66M | £159.68B | 6.99% | 77 Outperform | |
| Royal Bank Of Canada | 0.81% | $185.57M | $210.61B | 19.92% | 75 Outperform | |
| Siemens | 0.75% | $170.51M | €171.64B | 23.75% | 74 Outperform |
IDEV Technical Analysis
Neutral
―
Price Trends
80.49
Negative
78.88
Positive
74.62
Positive
Market Momentum
-0.32
Positive
43.07
Neutral
12.61
Positive
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For IDEV, the sentiment is Neutral. The current price of undefined is equal to the 20-day moving average (MA) of 80.62, equal to the 50-day MA of 80.49, and equal to the 200-day MA of 74.62, indicating a neutral trend. The MACD of -0.32 indicates Positive momentum. The RSI at 43.07 is Neutral, neither overbought nor oversold. The STOCH value of 12.61 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IDEV.
IDEV Peer Comparison
Comparison Results
Performance Comparison
IDEV
iShares Core MSCI International Developed Markets ETF
79.31
14.65
22.66%
VEA
Vanguard FTSE Developed Markets ETF
―
―
―
SCHF
Schwab International Equity ETF
―
―
―
SPDW
SPDR Portfolio Developed World ex-US ETF
―
―
―
IQLT
iShares MSCI Intl Quality Factor ETF
―
―
―
DFAI
Dimensional International Core Equity Market ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents